Divalproex sodium (Depakote ER)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Migraine, Epilepsy, Bipolar Disorder, Absence Seizures, Focal Onset Seizures

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Latest reported trial: NCT00060905 · Phase 3 · met primary endpoint · grade pending

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (8)
Bipolar Disorder
NCT00183443 · Palo Alto Veterans Institute for Research
2005-02 – 2010-11 · Bipolar Disorder, Schizophrenia
What this study did
NCT00194116 · University Hospitals Cleveland Medical Center
2004-09 – 2008-02 · Bipolar Disorder
What this study did
Migraine
Phase 2 (3)
Epilepsy
NCT00646711 · Abbott
2003-02 – 2003-12 · Pediatric Epilepsy
What this study did
Other / comorbidity
NCT00073164 · Abbott
started 2003-07 · Schizophrenia
What this study did
NCT00204503 · The University of Texas Medical Branch, Galveston
2003-06 – 2005-05 · Bipolar I or II Depression and Alcohol Abuse or Dependence
What this study did
Phase 1 (5)
Bipolar Disorder
NCT01094249 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2009-02 – 2009-04 · Schizophrenia, Bipolar Disorder, Psychotic Disorders
What this study did
Epilepsy
NCT01060228 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2009-01 – 2009-02 · Schizophrenia, Epilepsy
What this study did
Other / comorbidity
NCT04902105 · Emalex Biosciences Inc.
2021-05-13 – 2021-07-06 · Drug Interaction
What this study did
NCT01581775 · Dr. Reddy's Laboratories Limited
2011-01 – 2011-03 · Healthy
What this study did
NCT01581788 · Dr. Reddy's Laboratories Limited
2011-01 – 2011-03 · Healthy
What this study did
Phase 4 (9)
Bipolar Disorder
NCT00579280 · University of South Florida
2007-07 – 2010-12 · Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
What this study did
NCT00203528 · Tuscaloosa Research & Education Advancement Corporation
2004-01 – 2007-02 · Substance Abuse, Bipolar Depression
What this study did
NCT00181727 · Massachusetts General Hospital
2004-01 – 2006-11 · Bipolar Disorder, Mania
What this study did
NCT00199966 · Medical College of Wisconsin
2003-12 – 2005-11 · Bipolar Disorder
What this study did
Epilepsy
NCT00207935 · Children's National Research Institute
2005-08 – 2007-03 · Epilepsy, Mental Retardation, Developmental Disabilities
What this study did
Other / comorbidity
NCT00186186 · Stanford University
2004-01 – 2009-01 · Depression, Bipolar
What this study did
NCT00211796 · Montefiore Medical Center
2005-04 – 2007-04 · Autism
What this study did
NCT00211250 · Joliet Center for Clinical Research
2005-07 – 2006-09 · Mood Disorder
What this study did
Early phase / not applicable (1)
Epilepsy
NCT00318929 · Virginia Commonwealth University
2006-04 – 2008-01 · Elderly, Epilepsy, Seizures
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (2)
Other / comorbidity
NCT00647712 · Mylan Pharmaceuticals Inc
2004-12 – 2004-12 · Healthy
What this study did
NCT00648076 · Mylan Pharmaceuticals Inc
2004-12 – 2004-12 · Healthy
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Bipolar Disorder: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Divalproex Sodium (Depakote ER): this drugApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify Maintena)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
AsenapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionPartial signalFeatured results are non-efficacy only in this race
Iloperidone (Fanapt)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
Milsaperidone (VHX-896)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Olanzapine (Zyprexa)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Olanzapine / Samidorphan (Lybalvi)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Reliable signalNo reviewed efficacy summary in this indication
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Quetiapine (Seroquel)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal Consta)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Rykindo)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Uzedy)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
ZiprasidoneApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)Phase 3Small moleculeAlpha-2 adrenergic receptor (agonist)Reliable signalNo reviewed efficacy summary in this indication
Loxapine (Adasuve)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signalNo reviewed efficacy summary in this indication
Xanomeline / Trospium Chloride (Cobenfy)Phase 3Small moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)not yet gradedNo reviewed efficacy summary in this indication
ALTO-100Phase 2Small moleculeFirst-in-class oral small molecule neural plasticity enhancernot yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
ElunetiromPhase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
IcalcaprantPhase 2Small moleculeKappa-opioid receptor (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Lithium Salicylate / L-Proline (AL001)Phase 1/2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ABBV-1042
Phase 1(overall)
Small moleculeMuscarinic M4 receptornot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.